Bastiaan M. Privé

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Bastiaan M. Privé, Steffie M. B. Peters, Inge M. van Oort et al. · Clinical Cancer Research · 2021 · 98 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

Steffie M. B. Peters, Bastiaan M. Privé, Maarten de Bakker et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 88 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology

Bastiaan M. Privé, Bas Israël, Melline G.M. Schilham et al. · Prostate Cancer and Prostatic Diseases · 2020 · 69 citations

Medicine, Oncology, Radiology +14

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment

Steffie M. B. Peters, Regina Hofferber, Bastiaan M. Privé et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 65 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man

Bastiaan M. Privé, Yvonne H. W. Derks, Florian Rosar et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 46 citations · Full text

Medicine, Nuclear Medicine, Pharmacokinetics +15